In the BioHarmony Drug Report Database

"Preview" Icon

Midostaurin

Rydapt (midostaurin) is a small molecule pharmaceutical. Midostaurin was first approved as Rydapt on 2017-04-28. It is used to treat hematologic neoplasms, myeloid leukemia acute, and systemic mastocytosis in the USA. It has been approved in Europe to treat mastocytosis and myeloid leukemia acute. The pharmaceutical is active against receptor-type tyrosine-protein kinase FLT3. In addition, it is known to target dual specificity tyrosine-phosphorylation-regulated kinase 1A. Rydapt’s patents are valid until 2030-12-02 (FDA).

 

Trade Name

 

Rydapt
 

Common Name

 

midostaurin
 

ChEMBL ID

 

CHEMBL608533
 

Indication

 

hematologic neoplasms, mastocytosis, myeloid leukemia acute, systemic mastocytosis
 

Drug Class

 

Image (chem structure or protein)

Midostaurin structure rendering